Cargando…

Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis

Background: Heart failure with reduced ejection fraction (HFrEF) is a complex, chronic disease and is among the top causes of morbidity and mortality. Angiotensin receptor-neprilysin inhibitor drugs represented by sacubitril/valsartan are the key drugs for the treatment of HFrEF in western medicine,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Qian, Wang, Mengxi, Ding, Yuhan, Fan, Manlu, Tong, Huaqin, Chen, Jiandong, Yu, Peng, Shen, Le, Chen, Xiaohu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014182/ https://www.ncbi.nlm.nih.gov/pubmed/35444529 http://dx.doi.org/10.3389/fphar.2022.832782

Ejemplares similares

Clinical Effect of Qili Qiangxin Capsule Combined with Sacubitril-Valsartan in Patients with Chronic Heart Failure
por: Yao, Jiafang, et al.
Publicado: (2022)

Retracted: Clinical Effect of Qili Qiangxin Capsule Combined with Sacubitril-Valsartan in Patients with Chronic Heart Failure
por: Healthcare Engineering, Journal of
Publicado: (2023)

Sacubitril/valsartan in HFrEF – Should the aces up our sleeves be played earlier?
por: Boehmer, Andreas A., et al.
Publicado: (2019)

Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients
por: Campanile, Alfonso, et al.
Publicado: (2023)

Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting
por: Naser, Nabil, et al.
Publicado: (2022)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
por: Visco, Valeria, et al.
Publicado: (2022)

Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
por: Mapelli, Massimo, et al.
Publicado: (2023)

Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials
por: Wei, Jingjing, et al.
Publicado: (2022)

The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
por: Dattilo, Giuseppe, et al.
Publicado: (2023)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Penalized Model‐Based Unsupervised Phenomapping Unravels Distinctive HFrEF Phenotypes With Improved Outcomes Discrimination From Sacubitril/Valsartan Treatment Independent of MAGGIC Score
por: Sung, Kuo‐Tzu, et al.
Publicado: (2023)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Qili Qiangxin capsules for chronic heart failure: A GRADE-assessed clinical evidence and preclinical mechanism
por: Xing, Xiaoxiao, et al.
Publicado: (2023)

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin
por: Chen, Horng H., et al.
Publicado: (2020)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

A horse of a different colour: distinct mechanisms of HFpEF and HFrEF
por: Louch, William E.
Publicado: (2020)

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)

Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF
por: Sherwood, Andrew, et al.
Publicado: (2023)

Corrigendum to: Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
Publicado: (2023)

Effects of Qili Qiangxin Capsule on AQP2, V2R, and AT1R in Rats with Chronic Heart Failure
por: Cui, Xiangning, et al.
Publicado: (2015)

Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF
por: Ahmeti, Artan, et al.
Publicado: (2017)

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
por: Kristensen, Søren L., et al.
Publicado: (2017)

Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance
por: Berlot, Bostjan, et al.
Publicado: (2019)

Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy
por: Li, Zheng, et al.
Publicado: (2023)

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
por: Spannbauer, Andreas, et al.
Publicado: (2019)

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
por: Prausmüller, Suriya, et al.
Publicado: (2020)

FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF
por: Benes, Jan, et al.
Publicado: (2023)

Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
por: Zhang, Wenchao, et al.
Publicado: (2021)

Potential mechanisms of Qili Qiangxin capsule to prevent pulmonary arterial hypertension based on network pharmacology analysis in a rat model
por: Han, Xiao, et al.
Publicado: (2022)

The vasculature in HFpEF vs HFrEF: differences in contractile protein expression produce distinct phenotypes
por: Lyle, Melissa A., et al.
Publicado: (2019)

Ubiquitin‐proteasome‐system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF
por: Adams, Volker, et al.
Publicado: (2021)

Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF
por: Simon, Judit, et al.
Publicado: (2019)

The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients
por: Liao, Chia‐Te, et al.
Publicado: (2021)

Echocardiographic Parameters as Predictors for the Efficiency of Resynchronization Therapy in Patients with Dilated Cardiomyopathy and HFrEF
por: Pescariu, Silvius-Alexandru, et al.
Publicado: (2021)

Traditional Chinese medicine Qili qiangxin inhibits cardiomyocyte apoptosis in rats following myocardial infarction
por: XIAO, JUN, et al.
Publicado: (2015)

The Diagnostic and Prognostic Value of Plasma Galectin 3 in HFrEF Related to the Etiology of Heart Failure
por: Lu, Qun, et al.
Publicado: (2021)

Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis
por: Xu, Xiaoming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_34a9vhk7g29asvbi1giqfm99e0